Session Title Competition in Highly Regulated Sectors: Telecom, Health, and Financial Services



Similar documents
Influence, Information Overload, and Information Technology in HealthCare.

NBER WORKING PAPER SERIES INFORMATION TECHNOLOGY AND MEDICAL MISSTEPS: EVIDENCE FROM A RANDOMIZED TRIAL

Policy Forum. Understanding the Effects of Medicare Prescription Drug Insurance. About the Authors. By Robert Kaestner and Kelsey McCoy

Principles on Health Care Reform

Patient Safety: Achieving A New Standard for Care. Institute of Medicine Committee on Data Standards for Patient Safety November, 2003

United States HIT Case Study

What is an Evidence-Based, Value-Based Health Care System? (Part 1)

Introduction. What is Transparency in Health Care?

Lowering Costs and Improving Outcomes. Patient Engagement Issues. Nancy Davenport-Ennis President & CEO. September 8 th, 2009

Rising Premiums, Charity Care, and the Decline in Private Health Insurance. Michael Chernew University of Michigan and NBER

To Improve Outcomes & Clinical Efficiency

Integration of Pharmacists Clinical Services in the Patient-Centered Primary Care Medical Home. March 2009

PROPOSED US MEDICARE RULING FOR USE OF DRUG CLAIMS INFORMATION FOR OUTCOMES RESEARCH, PROGRAM ANALYSIS & REPORTING AND PUBLIC FUNCTIONS

Risk Adjustment: Implications for Community Health Centers

August 12, The Honorable Ron Wyden Chairman Committee on Finance United States Senate 219 Dirksen Senate Office Building Washington, DC 20510

STRATEGIC INNOVATIONS FOR AFFORDABLE, SUSTAINABLE HEALTH CARE:

Research on Tablet Splitting

Healthcare leaders should see to it that patients. Put the Patient in the Room IDEA

Impact of Direct-to-Consumer Advertising on Prescription Drug Spending

A STRATIFIED APPROACH TO PATIENT SAFETY THROUGH HEALTH INFORMATION TECHNOLOGY

Celebrating Pork. The Dubious Success of the Medicare Drug Benefit. Dean Baker. March 2007

Model of Intelligence

Physician s Guide to Certification for 08 EHRs

Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction

ACOs ECONOMIC CREDENTIALING BUNDLING OF PAYMENTS

Introduction of a Standard Drug Formulary in Hospital Authority

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

Business Intelligence (BI) for Healthcare Organizations

The Promise of Regional Data Aggregation

Critical Access Hospital Patient Safety Priorities and Initiatives: Results of the 2004 National CAH Survey

Economic Responses to the Problem of Drug Resistance

Arthritis Foundation Position Statement on Biosimilar Substitution

Elderly males, especially white males, are the people at highest risk for suicide in America.

How Incorporating EBP & CDS Can Improve Outcomes & Agency Efficiency

Introduction. Background

Module 11. How to Evaluate Claims of New Heart Failure Treatments and Cures

How To Fix An Electronic Medical Record

THE ROLE. Testimony United. of the. University. practicing. primary care. of care.

Quality Incentives for Medicare+Choice Plans

Research Based Health IT CRI Experience

Using Partial Capitation as an Alternative to Shared Savings to Support Accountable Care Organizations in Medicare

Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA Phone:

Health Coverage among 50- to 64-Year-Olds

practicematters For More Information UHCCommunityPlan.com

PRESCRIPTION DRUG COSTS FOR MEDICARE BENEFICIARIES: COVERAGE AND HEALTH STATUS MATTER

Electronic medical records

Clinical Nurse Specialists Practitioners Contributing to Primary Care: A Briefing Paper

Ben S Bernanke: Challenges for health-care reform

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy

Fulfil your potential with a career in medical communications

The Clinical Trials Process an educated patient s guide

Economics 4259: Economics of Health Services Grading and Assignments

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

STUDENT ARTICLE. Health Policy Issue with the Electronic Health Record

Why Are Health Care Costs Rising? Leading Experts/Real-World Data Identify Multiple Factors Across the System. March 2010

Can National Health Insurance Programs Improve Health Outcomes? Re-Examining the Case of the New Cooperative Medical Scheme in Rural China

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products

Statement of the American Pharmacists Association Thomas E. Menighan, BSPharm, MBA, ScD (Hon), FAPhA Executive Vice President and CEO.

Kaiser Permanente Southern California Depression Care Program

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry

STONY BROOK UNIVERSITY HEALTH PULSE OF AMERICA February 18 March 8, 2004 HEALTH CARE AND THE 2004 PRESIDENTIAL ELECTION

Introduction. The Evolution of the Data Management Role: The Clinical Data Liaison

Improving the Value of an EAP Through a Coordinated Drug Intervention

Racial and ethnic health disparities continue

Pain Management Tools Information Technology. Mohit Rastogi, MD The University of Michigan Department of Anesthesiology Division of Pain Medicine

ELECTRONIC MEDICAL RECORDS. Selecting and Utilizing an Electronic Medical Records Solution. A WHITE PAPER by CureMD.

Markle Survey on Health in a Networked Life 2010

WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

ONE MICHIGAN: THE PROBLEM OF THE UNINSURED IS EVERYONE S PROBLEM

c. determine the factors that will facilitate/limit physician utilization of pharmacists for medication management services.

End Stage Renal Disease (ESRD)

Medical Information Systems - Advantages and Limitations

NOTICE OF PRIVACY PRACTICES This Notice is effective March 26, 2013

This PDF is a selection from a published volume from the National Bureau of Economic Research

Financial Handbook For Liver Transplant Patients

Teaching Health Policy and Politics in U.S. Schools of Public Health

REQUEST FOR PROPOSAL WEBSITE DESIGN, DEVELOPMENT AND HOSTING

ECONOMICS INTERACTIONS WITH OTHER DISCIPLINES Vol. I - Costs of Health Care Throughout the World - R.E. Santerre

GOVERNMENT OF THE DISTRICT OF COLUMBIA Department of Health

Re: CMS-1345-P; Medicare Program; Medicare Shared Savings Program: Accountable Care Organizations; Proposed Rule

Fund Health Benefits Fund

PRACTICE BRIEF. Preventing Medication Errors in Home Care. Home Care Patients Are Vulnerable to Medication Errors

Models to Identify and Support Clinical Trial Participants

105 CMR: DEPARTMENT OF PUBLIC HEALTH 105 CMR : THE ADMINISTRATION OF PRESCRIPTION MEDICATIONS IN PUBLIC AND PRIVATE SCHOOLS

How To Protect Your Privacy At A Clinic

November 22, RE: File code CMS-1345-NC. Dear Dr. Berwick:

Agency # REGULATION 9 PHARMACEUTICAL CARE/PATIENT COUNSELING

EXECUTIVE SUMMARY. June Pathways for Physician Success Under Healthcare Payment and Delivery Reforms. Harold D. Miller

Quality Scores Monitoring and Reporting

Putting Reliable Health Care Performance Measurement Systems into Practice

Health Information Technology in the United States: Information Base for Progress. Executive Summary

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise

Neal Rouzier responds to the JAMA article on Men and Testosterone

Issue Brief Findings from HSC

Depression in Older Persons

Innovations in Value-Based Insurance Design Improving Care and Bending the Cost Curve. A. Mark Fendrick, MD

Networked Medical Devices: Essential Collaboration for Improved Safety

Schindler Elevator Corporation

Transcription:

Session Title Competition in Highly Regulated Sectors: Telecom, Health, and Financial Services Session Chair Sharon Oster (Yale University) Manuscript title Information Overload and Information Technology in Health Care Authors James B. Rebitzer, Case Western Reserve University and National Bureau of Economic Research. Contact information: Case Western Reserve University, 11119 Bellflower Road, Cleveland, Ohio 44106 USA, Phone: (216) 368-4110, Fax: (216) 368-5039, E-mail: james.rebitzer@case.edu. Mari Rege, Case Western Reserve University. Contact information: Case Western Reserve University, 11119 Bellflower Road, Cleveland, Ohio 44106 USA, Phone: (216) 368-4185, Fax: (216) 368-5039, E-mail: mari.rege@case.edu. Christopher Shepard, MD, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, Ohio 44106, Phone: (216) 707-9539.

Information Overload and Information Technology in Health Care James B. Rebitzer, Mari Rege and Chris Shephard Economists who study incentives in organizations have given much attention to problems that arise when information is scarce. Indeed the premise of the vast literature on optimal incentives is that principals have incomplete knowledge about agents and their actions. It has long been recognized, however, that other important features of organizations are the result of a superabundance of information (Simon 1970), but economic research on these aspects of organizations is less well developed. In this paper we consider economic issues that arise when agents are presented with more information than they can handle. Our purpose is to assess ways in which new information technology (IT) can mitigate problems that result from this information overload. The focus of our study is information overload among physicians. In medicine, the number and variety of diseases and treatments threaten to overwhelm the information processing capacities of individual doctors. This complexity is magnified by the rapid growth of new, medically- relevant knowledge. Failure to cope with this flood of information can cause physicians to overlook important new treatments or clinical trails altering the recommended use of existing treatments. The net result is a degradation of care quality and a slower diffusion of new medical innovations (Institute of Medicine 2000 and 2001) In this paper we investigate how IT can help physicians cope with information overload and therefore improve care quality and the rate of diffusion of new innovations. Our analysis focuses on a particular type of computer system that has drawn considerable attention in the medical community and in public policy debates: a computer based decision support tool that 1

scans digitized patient records and recommends treatment protocols to physicians when it finds a deviation from best practice. The paper proceeds as follows. In section one, we briefly discuss evidence suggesting a slow and uneven diffusion of new medical knowledge. Slow diffusion is likely the result of physicians being unable to keep up with newly emerging protocols. Thus in section two we outline a simple conceptual framework for thinking about physician learning in an environment with too much new information. In section three we present evidence from a randomized prospective trial suggesting that computer based decision support tools substantially enhance the diffusion of new medical knowledge among physicians. From a public policy perspective this is an important finding. Reducing the lag between the discovery and application of new clinical developments is likely to improve quality of care and increase the returns to innovation. We conclude by considering whether private incentives to invest in computer based decision support technology are sufficient to assure adequate investment. I. The Slow and Uneven Diffusion of Innovations in Medicine The broadest evidence suggesting a slow diffusion of innovations comes from the vast medical literature on geographic variation in practice patterns. The care delivered by doctors varies greatly from one geographic region to another in ways that cannot be accounted for by underlying differences in patient population, medical prices, technology or other exigencies (Phelps 2000, Skinner, Fisher and Wennberg 2001). In the absence of other explanations, it is hard to escape the implication that these variations are due to the incomplete diffusion of the best medical practices to physicians. Consider, for example, the case of heart attacks. Some states spend 40-60% more per patient than others with no improvement in outcomes. This 2

suggests substantial productivity differences across regions that are partly the result of the uneven diffusion of new innovations (Skinner & Staiger 2005, p. 20). The substantial resources that drug companies spend promoting their products also suggest an imperfect diffusion of medical knowledge. If the results of clinical studies percolated swiftly to providers, pharmaceutical companies high-powered marketing campaigns and sales forces would not be effective. The literature suggests, however, that physicians are affected by marketing. Avorn (2004) documents a number of instances where pharmaceutical marketing appeared to successfully promote the use of favored drugs even when there was good clinical evidence that these drugs were ineffective or less effective than inexpensive alternatives. A recent econometric study of the diffusion of anti-ulcer drugs by Berndt et al. (2003, p. 262) finds that equilibrium market shares are strongly determined by the resources drug companies devote to advertising. II. Conceptual Framework for Physician Learning Physicians are highly trained and highly motivated professionals. It is reasonable to assume, therefore, that the slow and uneven distribution of new and effective therapies is not the result of simple inattention. A more likely explanation is that it is difficult for physicians to keep up with the rapidly changing state of medical knowledge and to understand what these changes mean for the treatment of specific patients. In this section we outline a simple model for understanding how physicians learn about medical innovations relevant to their patients 1. Our starting point is that in the acquisition of new medical knowledge, physicians are hampered by two cognitive limitations: 1 For details on the formal model see Rebitzer, Rege and Shepard (2005). 3

1) The flow of new medical knowledge exceeds the information processing capacities of individual physicians. 2) It is difficult for physicians to link the description of new medical knowledge to the conditions of specific patients. Faced with these cognitive limitations, physicians will rely on the recommendations of their colleagues to economize on the costs of information acquisition. Colleagues are good at suggesting highly relevant treatments, but due to limits on their own cognitive abilities they are generally not very effective at keeping abreast of the newest procedures. Thus physicians will also devote time to independent reading in medical journals. Reading journal articles may expose the physician to the newest innovations, but they may fail to identify the patients for which these treatments are relevant. Rational physicians will therefore rely on both their colleagues recommendations and independent reading in new medical journals. Into this web of influence we now introduce IT enabled decision support systems. In these systems an artificial intelligence program compares a patient s treatment with best practice protocols drawn from the medical literature. If a discrepancy between actual and recommended care is observed, a message is sent to the physician. This message will link a specific patient with a specific medical literature, allowing the physician to consider the relevance of the literature to the patient s particular circumstances. In contrast to traditional learning modalities (colleagues recommendations and independent reading of medical journals) the computer based decision support tools are capable of suggesting treatments that are both new and relevant to the care of a specific patient. Heightened timeliness and specificity enhances physician learning and also displace the traditional avenues of information acquisition. III. The Effectiveness of Information Technology: Evidence from a Randomized Trial In this section we present new evidence from a randomized trial indicating that IT based decision support tools enhance the rate of diffusion of new medical knowledge. The data we use 4

comes from a randomized prospective trial of a decision support technology in which HMO members under age 65 were randomly assigned to study/control groups 2. Data from insurance billing records, laboratory feeds and pharmacies were then combined into a virtual electronic medical record and the information in these records was passed through a sophisticated program that scanned for deviations from evidence based, best-practice protocols. For patients in the study group, the information was scanned in real time and, if an issue was detected, a message was sent to the physician. The message stated the name of the patient, described the potential issue, and referenced the relevant medical literature. After the trial was completed, the control group data was analyzed and messages were generated that would have been sent to physicians if the control patient had been in the study group. The trial therefore allowed us to compare the rate of resolution of issues when physicians enjoyed decision support with the rate of resolution of the same issues when no support was available. We would like to know if the messages from the decision support tool increased the rate of adoption of new medical evidence. For this purpose we chose to look at the class of medications known as ACE-inhibitors. ACE-inhibitors were first approved by the FDA in 1981 for treatment of severe hypertension. Shortly before the randomized trial began in 2001, several major clinical trials, the most important of them referred to as the HOPE trial, established the beneficial effect of ACE-inhibitors in patients with mild and moderate hypertension, heart failure, past heart attacks, chronic renal disease, certain subgroups of diabetics and patients at high risk for cardiovascular events. Taken together, these trials greatly expanded the number of patients for whom an ACE-inhibitor was indicated. 2 For detailed descriptions of this trial see Javitt, Reisman et. al. (2005); and Javitt, Rebitzer and Reisman (2004). 5

In column one of Table 1 we analyze the eventual use of ACE-inhibitors for patients who didn t use these medicines but should have been using them on the basis of the HOPE trial findings. The dependent variable is a dummy variable equal to 1 if ACE-inhibitors were used during the course of the study while the dummy variable Study identifies patients assigned to the study group. Patients in the study group, whose physicians received computer generated messages regarding ACE-inhibitors, were thirteen percentage points more likely to start using the medicine than those in the control group: representing an increase of almost 100 percent. Comparing columns 1 and 2 it is clear that the decision support system had a more substantial effect on the relatively new ACE-inhibitor recommendation than on all other recommendations that suggested adding a drug. At the time of our study, the new clinical evidence regarding Ace inhibitors were widely promoted to physicians via the conventional routes of disease management programs and journal articles. We suspect on the basis of informal conversations that the computer generated messages had extra influence because they were reliable, timely, and focused physician attention on a specific issue concerning a specific patient. IV. Conclusions: Public Policy and Private Incentives Information overload acts as a drag on the diffusion of new knowledge and hence on the dynamic efficiency of the health care system. Using IT to alleviate this drag improves care quality and increases the return to innovation. This last outcome is desirable because it can stimulate more rapid innovation. Just as small increases in productivity growth rates accumulate over time to transform living standards; so enhanced innovation rates resulting from the faster diffusion of new knowledge should yield transformations in the quality of health care Most of the expense of IT based decision support systems are currently borne by care providers and/or insurance companies. Our model of physician learning suggests, however, that 6

neither of these parties have incentives adequate to support optimal levels of IT investments. The problem results directly from the way physicians learn about new innovations. If a doctor hears about ACE-inhibitors from the IT system, she will likely transmit that information to other physicians who do not have the benefit of computerized decision support. These spillovers improve care quality, but the benefits do not accrue to the physicians and insurers who pay for the system. The conventional economic response to positive externalities is to internalize them with subsidies financed by lump sum taxes. This approach is, however, famously difficult to implement. An alternative approach might be feasible because what appear as externalities to health care providers and insurers are actually sources of revenue to other market actors. The pharmaceutical and device manufacturers profit from the informal spread of new information about their products and therefore have more powerful incentives than providers and insurers to promote the spread of computer based decision support tools. Our model suggests that this finance scheme is also likely to yield unsatisfactory outcomes. This is because the limitations on physician cognitive capacities that lead to information overload also make physicians receptive to marketing messages sent via computer based decision support systems. Using the IT system to market products rather than to educate physicians about new protocols undermines the technology s effectiveness and also crowds out other, higher quality, information acquisition activities. We are left to conclude that appropriate investments in IT based decision support tools can enhance the quality of health care and the dynamic efficiency of the health care system. Designing public policies that assure appropriate investments in IT based decision support 7

systems in the health care setting is a difficult and important area for future research (President s Information Technology Advisory Committee, 2004). 8

References Avorn, J. Powerful Medicines. The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf, 2004. Berndt, E. R., R. S. Pindyck and P. Azoulay. Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs. Journal of Industrial Economics, 2003, 51(2), pp. 243-270. Institute of Medicine Committee on Quality of Health Care in American. To Err is Human: Building a Safer Health System (L. T. Kohn, J. M. Corrigan and M. S.Donaldson, eds.). Washington DC: National Academy Press, 2000. Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality Chasm: A. Washington D.C,: National Academy Press, 2001. Javitt, J., G. Steinberg, J. Couch, T. Locke, J. Jacques, I. Juster and L. Reisman "Use of a Claims Data-Based Sentinel System to Improve Compliance with Clinical Guidelines: Results of a Randomized Prospective Study." Am J Managed Care, 2005, 11, pp. 21-31. Javitt, J., J. Rebitzer and L. Reisman. Information Technology and Medical Errors: Evidence from a Randomized Trial. working paper, Case Western Reserve University, 2004. Phelps, C. E. Information Diffusion and Best Practice Adoption. in A.J. Culyer and J.P. Newhouse, eds., Handbook of Health Economics. Volume 1, Elsevier Science B.V., 2000, pp. 223 264. President s Information Technology Advisory Committee, National Coordination Office for Information. Revolutionizing Health Care Through Information Technology. Arlington, VA, June 30 2004. Rebitzer J., M. Rege and C. Shepard. Innovation, Influence and Information Technology in Health Care, working paper, Case Western Reserve University, 2005. Simon, H. "Information Storage as a Problem in Organizational Design", in Goldberg (editor), Behavioral Approaches to Modern Management, Göteborg: BAS, 1970. Skinner J. and D. Staiger."Technological Diffusion from Hybrid Corn to Beta Blockers." NBER Working Paper, 2004. Skinner J., E. Fisher and J Wennberg, The Efficiency of Medicare. NBER Working Paper Paper, 2001. 9

Table 1 (1) (2) Probit Probit Successful Resolution "Add Ace Inhibitor for Hope Qualifier Drug" Message Successful Resoltion for Any Other "Add a Drug" Message [0.141] [0.258] Study 0.130 0.035 (2.82)* (0.69) Number of patients 311 290 Number of patients in study group 155 166 Log pseudo-likelihood -154.018-158.877 In column 1, the sample consists of participants who would have qualified for an Ace inhibitor on the basis of the HOPE trial criteria, but who were not receiving the drug according to computer records. In column 2 the sample consists of participants who received an "add a drug" message other than that in column 1. The message is successfully resolved if there is evidence in the data base that the patient started the relevant drug within 270 days after the message was sent. Robust z statistics in parentheses. [ ] is mean of dep. var. in the control group in 2001 * significant at 5%; ** significant at 1% Coefficients are expressed as "derivatives". Thus in column 1 members in the study group were 13 percentage points more likely to have resolved the issue successfully than those in the control group.